Table 2. Multivariate regression analysis of EC.

Pathological features	Group	Progression-free survival				Total survival
		HR	95% CI	P		HR	95% CI	P
Age	<50	–				–
	≥50	0.98	0.42–1.64	0.861		1.06	0.72–1.82	0.478
LN	N	–				–
	P	3.89	1.67–6.89	0.008*		4.32	1.68–6.75	0.007*
Histological grade	G1	–				–
	G2	2.12	1.09–3.98	0.047a		1.08	0.64–2.85	0.361
	G3	2.56	1.23–4.23	0.023*		1.98	1.09–3.68	0.042*
Myometrial invasion	Non	–				–
	Light	1.35	0.78–2.78	0.671		1.45	0.73–2.92	0.285
	Deep	2.09	0.87–4.28	0.187		1.89	1.08–2.89	0.048*
Pathological types	others	–				–
	ESAC	1.46	0.87–3.76	0.372		1.28	0.98–3.98	0.062
	EAC	0.98	0.46–2.98	0.792		0.83	0.47–1.89	0.398
FIGO	Stage I	–				–
	Stage II	2.78	0.93–2.78	0.058		3.09	1.32–3.95	0.011*
	Stage III	3.67	1.78–5.78	0.003*		4.65	2.32–6.89	<0.001**
Tumor size	<4 cm	–				–
	≥4 cm	1.65	0.75–3.29	0.321		1.87	0.89–4.09	0.078
ER	N	–				–
	P	3.64	2.65–7.83	0.000**		2.98	2.13–6.43	0.001**
PR	N	–				–
	P	2.31	1.56–8.34	0.002*		1.78	1.21–4.68	0.031*
Tra2-beta1	Low expression	–				–
	High expression	2.89	1.15–6.43	0.043*		3.21	1.98–8.56	0.003*

*, P<0.05; **, P<0.001. HR, hazard ratio; CI, confidence interval; LN, lymph node metastasis; EAC, endometrioid adenocarcinoma; ESAC, endometrial adenoid squamous carcinoma; P, positive; N, negative.